ReviewPharmacological research2017
Tumor-targeted nanomedicines for cancer theranostics.
Review in Pharmacological research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
91 citing papers in PubMed, 236 citations in OpenAlex.
- Correlation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Trial
- Advancing Treatment of Degenerative Eye Diseases at the Nanoscale.Smart medicine · 2026Review
- Advances and Prospects in MOF-Based Platforms for Tumor Hyperthermia.Bioengineering (Basel, Switzerland) · 2026Review
- Smart Vesicle Therapeutics: Engineering Precision at the Nanoscale.Pharmaceutics · 2025Review
- Transformable self-assembling peptide nanoplatforms with tumor microenvironment responsiveness for tumor stem cell suppression and immunomodulation.Materials today. Bio · 2025Article
- Targeted delivery and controlled release of polymeric nanomedicines for tumor therapy.Fundamental research · 2025Review
- Application of nanomedicines in tumor immunotherapy.Journal of molecular cell biology · 2025Review
- Inhaled PAMAM-based nano-formulation prolonged lung retention for alleviating pulmonary inflammation of COPD.Materials today. Bio · 2025Article
- Ti-Based Metallic Biomaterials for Antitumor Applications.Materials (Basel, Switzerland) · 2025Review
- Exosomes in glioma: mechanistic insights on biological, therapeutic, and diagnostic perspective.Therapeutic delivery · 2025Review
- Engineered bacteria for near-infrared light-inducible expression of cancer therapeutics.Nature cancer · 2025Article
- ROS-responsive nanoparticles with selenomethionine for ferroptosis modulation in abdominal aortic aneurysm.iScience · 2025Article
- Advancements in nanotheranostics for glioma therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Complexed hyaluronic acid-based nanoparticles in cancer therapy and diagnosis: Research trends by natural language processing.Heliyon · 2025Article
- Influence of Nanomedicine as a Smart Weapon for Multidrug Resistance in Cancer Therapy.Current pharmaceutical biotechnology · 2025Review
- Targeted drug delivery in neurodegenerative diseases: the role of nanotechnology.Frontiers in medicine · 2025Review
- Molecular Targets and Nano-Technological Approaches in the Treatment of Hepatic Carcinoma.Current cancer drug targets · 2025Review
- Unveiling Theranostics: Nanocomplex-Assisted Photodynamic Eradication of Aggressive Cancer Cells and Modulation of Tumor-Associated Macrophages.International journal of nanomedicine · 2025Article
- Assessing Therapeutic Nanoparticle Accumulation in Tumors Using Nanobubble-Based Contrast-Enhanced Ultrasound Imaging.ACS nano · 2024Article
- The application of bacteria-nanomaterial hybrids in antitumor therapy.Journal of nanobiotechnology · 2024Review
31 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Chemotherapeutic drugs have multiple drawbacks, including severe side effects and suboptimal therapeutic efficacy. Nanomedicines assist in improving the biodistribution and target accumulation of chemotherapeutic drugs, and are therefore able to enhance the balance between efficacy and toxicity. Multiple types of nanomedicines have been evaluated over the years, including liposomes, polymer-drug conjugates and polymeric micelles, which rely on strategies such as passive targeting, active targeting and triggered release for improved tumor-directed drug delivery. Based on the notion that tumors and metastases are highly heterogeneous, it is important to integrate imaging properties in nanomedicine formulations in order to enable non-invasive and quantitative assessment of targeting efficiency. By allowing for patient pre-selection, such next generation nanotheranostics are useful for facilitating clinical translation and personalizing nanomedicine treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.